Kisspeptin (KP-10)

KISS1 Gene Product | Reproductive Neuropeptide

Weight: 1,213.42 Da (KP-10) / 6,087 Da (KP-54)
Half-life: ~4 minutes (KP-10), ~28-32 minutes (KP-54)
Chain: 10-54 amino acids
4 studies
2025 latest
2 recent
Emerging
Dose 100-200 mcg per injection
Frequency Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Cycle 2-4 weeks
Storage Lyophilized: Room temperature. Reconstituted: 2-8°C. KP-10: use within 7 days. KP-54: use within 14 days
Accumulation Plotter

Community Research

Join others researching Kisspeptin — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Kisspeptin acts as a master regulator of the reproductive system, stimulating GnRH neurons essential for puberty, fertility, and reproductive function.

Mechanism of Action

Binds to GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which stimulates pituitary LH/FSH secretion and gonadal steroid production.

01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential

Molecular Data

Molecular Weight
1,213.42 Da (KP-10) / 6,087 Da (KP-54)
Chain Length
10-54 amino acids
Type
Neuropeptide family (RFamide)
Amino Acid Sequence
One-letter: ??NWNSFGLRF?
H₂N
H
? 1
O ‖ C
N
H
? 2
O ‖ C
N
N 3
O ‖ C
N
W 4
O ‖ C
N
N 5
O ‖ C
N
S 6
O ‖ C
N
F 7
O ‖ C
N
H
G 8
O ‖ C
N
L 9
O ‖ C
N
R 10
O ‖ C
N
F 11
O ‖ C
N
H
? 12
COOH
Kis
1

Kisspeptin

Position 1

10:
2

10: Tyr

Position 2

Asn
3

Asparagine

Position 3

Trp
4

Tryptophan

Position 4

Asn
5

Asparagine

Position 5

Ser
6

Serine

Position 6

Phe
7

Phenylalanine

Position 7

Gly
8

Glycine

Position 8

Leu
9

Leucine

Position 9

Arg
10

Arginine

Position 10

Phe
11

Phenylalanine

Position 11

NH2
12

NH2

Position 12

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Reproductive
Hypogonadotropic Hypogonadism most effective

Restores reproductive hormone secretion in functional or congenital cases by stimulating dormant GnRH axis.

IVF Ovulation Trigger most effective

Triggers oocyte maturation with 45% live birth rate and zero severe OHSS cases; safer than hCG.

Hypothalamic Amenorrhea effective

Restores reproductive hormone pulsatility in women with hypothalamic amenorrhea.

Sexual Function
Hypoactive Sexual Desire Disorder (Men) effective

Modulates sexual brain processing; increases penile tumescence by 56% vs placebo.

Hypoactive Sexual Desire Disorder (Women) effective

Modulates sexual and attraction brain processing; increases self-reported sexiness.

Metabolic
Energy Metabolism moderate

Preclinical evidence suggests influence on energy expenditure and activity levels.

Dosing Protocols

Standard administration route; allows precise dosing and rapid hormone stimulation.

GoalDoseFrequencyRoute
Gonadotropin stimulation100-200mcgSingle dose or 2-3x weeklySubQ
Fertility support0.4-1.0 nmol/kg (50-150mcg)As directed by physicianSubQ (KP-54)
Sexual function (clinical)1 nmol/kg/h75-minute IV infusionIV infusion

Reconstitution Instructions

Materials Needed:
  • Bacteriostatic water (BAC water)
  • Insulin syringes (0.5-1 mL)
  • Alcohol swabs
  • Sterile work surface
  1. 1 Clean work area and hands thoroughly with alcohol
  2. 2 Calculate required BAC water volume
  3. 3 Draw calculated water into syringe
  4. 4 Inject slowly down vial side (not directly onto powder)
  5. 5 Gently swirl until dissolved (never shake)
  6. 6 Store in refrigerator at 2-8°C
  7. 7 Use within 7 days for KP-10; 14 days for KP-54

Interactions

++
GnRH
Kisspeptin stimulates GnRH release; works upstream in reproductive axis.
synergistic
+
HCG
Serves as potentially safer alternative for IVF ovulation triggering.
compatible
+
Testosterone
Restores natural testosterone production through LH stimulation.
compatible
+
Estrogen
Kisspeptin function modulated by sex steroids in feedback loops.
compatible

What to Expect

Hours 2-5
LH surge peaks at 3-5x baseline
Hours 12-14
LH returns to baseline
Days 1-2
Testosterone/estradiol increase in response to LH
Weeks 2-4
Potential improvements in sexual function and libido

Side Effects & Safety

Common Side Effects

  • Minimal acute side effects reported
  • Potential mild cardiovascular effects

Stop Signs - Discontinue if:

  • Ovarian hyperstimulation signs: severe pelvic pain, bloating, nausea
  • Chest pain or cardiovascular symptoms
  • Severe headaches or visual disturbances
  • Persistent injection site reactions

Contraindications

  • Not recommended during pregnancy or breastfeeding
  • Caution with cardiovascular disease history
  • Daily dosing causes receptor desensitization

Quality Checklist

Good Signs

  • White, fluffy powder; proper freeze-drying indicated
  • Clear solution after reconstitution; no particles or cloudiness
  • Protected from light in amber/opaque vials

Warning Signs

  • Slight compaction acceptable if dissolves completely with gentle swirling

Bad Signs

  • Discoloration or yellowing indicates oxidation/degradation
  • Cloudy after reconstitution indicates degradation or contamination

References

  • Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
    Mills EG, Sheridan H, Bhushan S, et al. (Dhillo WS senior author)
    JAMA Network Open (2023)

    32 men completed trial. Kisspeptin-54 IV (1 nmol/kg/h for 75 min) significantly modulated sexual brain processing and increased penile tumescence by up to 56% vs placebo. Potential as first pharmacological treatment for male HSDD.

  • Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
    Sheridan H, Mills EG, Sherwood RA, et al. (Jayasena CD, Dhillo WS senior authors)
    JAMA Network Open (2022)

    Double-masked, placebo-controlled, 2-way crossover trial in women with HSDD. Kisspeptin modulated sexual and facial attraction brain processing, with hippocampal activation correlating with distress and reduced sexual aversion.

  • Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS During IVF Therapy
    Jayasena CN, Abbara A, Comninos AN, et al. (Dhillo WS senior author)
    Journal of Clinical Endocrinology & Metabolism (2015)

    Live birth rates of 45% overall per transfer; 62% at optimal 9.6 nmol/kg dose. Zero cases of moderate, severe, or critical OHSS. Oocyte maturation in 95% of women.

  • Intranasal Kisspeptin Administration Rapidly Stimulates Gonadotropin Release in Humans
    Sheridan H, Sherwood RA, Sheridan C, et al. (Dhillo WS senior author)
    eBioMedicine (2025)

    Intranasal kisspeptin-54 (12.8 nmol/kg) rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L). Formulation stable for 60 days at 4°C.

Related Peptides

HCG compatible

Serves as potentially safer alternative for IVF ovulation triggering.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.